In short
Clinical trials investigating Adct-402 are studying it in people with previously untreated diffuse large B-cell lymphoma and related B-cell lymphomas. The main goal is to assess how well the treatment works and how well it is tolerated in unfit or frail patients, including those with heart problems.
Key points
- Clinical trials investigating Adct-402 are focused on people with previously untreated diffuse large B-cell lymphoma and related lymphomas. The main study is a Phase 2 open-label trial in unfit, frail, and some heart-affected patients. Researchers are looking at complete response rate, which shows how many patients have no detectable cancer by the study rules. The trial also checks tolerability, meaning how many patients can finish the planned treatment. One group includes patients who are not eligible for standard R-mini-CHOP treatment. The available trial listed here is completed and enrolled 93 patients.
Clinical trial overview
The available trial of Adct-402 was a Phase 2 study called LOTIS-9. It studied a treatment plan using Loncastuximab Tesirine with rituximab in people with previously untreated lymphoma.
The study was open-label, which means the patients and the study team knew what treatment was being given. It was completed and enrolled 93 people.
Who was studied
The trial focused on people with previously untreated diffuse large B-cell lymphoma (DLBCL). It also included patients with high-grade B-cell lymphoma and grade 3b follicular lymphoma.
Two study groups were described in the record. Cohort A included unfit patients, while Cohort B included frail patients or patients with cardiac comorbidities, meaning other heart-related health problems.
Cohort B also included people who were not eligible for standard R-mini-CHOP, a lower-intensity treatment plan used for some patients who cannot receive stronger therapy.
What the trial measured
The main outcome was complete response rate, which means the share of patients whose cancer could not be found by the study’s response rules. This was measured in both Cohort A and Cohort B.
For Cohort B, the trial also measured tolerability, which is how well patients can stay on treatment. In this study, tolerability was defined by the percentage of patients who finished 4 treatment cycles out of all patients in that group.
Trial design and phase
This was a Phase 2 interventional study. Interventional means the researchers gave a treatment and then measured the results, rather than only observing what happened naturally.
The brief summary says the study looked at a response-adapted treatment of Lonca-R in unfit patients and in frail patients or patients with heart comorbidities. A response-adapted plan means treatment decisions were based on how the disease responded during the study.
What the trial record shows
The trial record shows that NCT05144009 is completed and includes 93 participants. The study was designed to learn whether this approach could produce complete responses and whether frail or heart-affected patients could tolerate the treatment plan.
Based on the record, the main focus was not on healthy volunteers or on advanced disease after many prior treatments. Instead, it focused on people who had not yet been treated and who might need a less intensive approach because of weakness, frailty, or other health problems.